Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

British Journal of Haematology

Volumn 145, Issue 3, 2009, Pages 373-375

  Marin, David ^a,b   Khorashad, Jamshid S ^b   Foroni, Letizia ^b   Milojkovic, Dragana ^b   Szydlo, Richard ^b   Reid, Alistair G ^b   Rezvani, Katayoun ^b   Bua, Marco ^b   Goldman, John M ^b   Apperley, Jane F ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic leukaemia; Imatinib; Molecular studies

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MULTIVARIATE ANALYSIS; MUTATION; ONCOGENE PROTEINS V-ABL; PHOSPHOTRANSFERASES; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RISK; SURVIVAL RATE; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 64149123286     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07646.x     Document Type: Article

References (8)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809 1820.
2. Cross, N.C., Feng, L., Chase, A., Bungey, J., Hughes, T.P. Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 1929 1936.
3. Druker, B., Guilhot, F., O'Brien, S., Gathmann, I., Kantarjian, H., Gattermann, N., Silver, R., Goldman, J., Cervantes, F., Hochhaus, A., Powell, B., Gabrilove, J., Rousselot, P., Reiffers, J., Cornelissen, J., Hughes, T., Valent, T., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Nielsen, J.L. Larson, R. (2006) Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. New England Journal of Medicine, 355, 2408 2417.
4. Kaeda, J., O'Shea, D., Szydlo, R.M., Olavarria, E., Dazzi, F., Marin, D., Saunders, S., Khorashad, J.S., Cross, N.C., Goldman, J.M. Apperley, J.F. (2006) Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 107, 4171 4176.
5. Khorashad, J., de Lavallade, H., Apperley, J., Milojkovic, D., Reid, A., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. Marin, D. (2008) The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression. Journal of Clinical Oncology, 26, 4806 4813.
6. de Lavallade, H., Apperley, J.F., Khorashad, J.S., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. Marin, D. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology, 26, 3358 3363.
7. Marin, D., Kaeda, J., Szydlo, R., Saunders, S., Fleming, A., Howard, J., Andreasson, C., Bua, M., Olavarria, E., Rahemtulla, A., Dazzi, F., Kanfer, E., Goldman, J.M. Apperley, J.F. (2005) Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia, 19, 507 512.
8. Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J.S., de Lavallade, H., Reid, A.G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., Pavlu, J., Klammer, M., Kaeda, J., Goldman, J.M. Apperley, J.F. (2008) European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood, 112, 4437 4444.